Download PDF
Hamostaseologie 2005; 25(04): 333-344
DOI: 10.1055/s-0037-1619669
Original Article
Schattauer GmbH

Antikoagulanzien und Thrombolytika beim akuten Koronarsyndrom

Anticoagulant and thrombolytic agents in acute coronary syndrome
B. Saurbier
1   Abteilung Innere Medizin III – Kardiologie und Angiologie, Medizinische Universitätsklinik Freiburg
,
C. Bode
1   Abteilung Innere Medizin III – Kardiologie und Angiologie, Medizinische Universitätsklinik Freiburg
› Author Affiliations
Further Information

Publication History

Publication Date:
27 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Unter dem Begriff des akuten Koronarsyndroms (ACS) werden die instabilen und somit lebensbedrohlichen Formen der klinisch manifesten koronaren Herzkrankheit zusammengefasst. Dies sind die instabile Angina pectoris, der Nicht-ST-Strecken-hebende (NSTEMI) und der ST-Strecken-hebende Myokardinfarkt (STEMI) sowie der plötzliche Herztod.

Wichtigstes therapeutisches Ziel ist die rasche und vollständige Wiedereröffnung der eingeengten oder verschlossenen Koronararterie, um den Verlust an kontraktiler Muskelmasse zu minimieren. Unangefochtene Therapie der Wahl ist hierfür die primäre perkutane Koronarintervention (PCI), wenn diese innerhalb von zwei Stunden von einem erfahrenen Team vorgenommen werden kann. Da diese Vorausetzung in Deutschland nur an 20% der Myokardinfarkt-Patienten versorgenden Kliniken erfüllt ist, kommt der medikamentösen Therapie weiterhin eine große Bedeutung zu. Neben einer schnellen Primärversorgung ist auch die optimale gerinnungs- und aggregationshemmende Therapie während der Koronarintervention mit dem Primär- und Langzeiterfolg eng korreliert. Entsprechend den aktuellen Erkenntnissen ist es die Kombinationstherapie verschiedener Substanzen, die unter Berücksichtigung von Kontraindikationen das bestmögliche Ziel erreichen lässt.

Summary

The term acute coronary syndrome (ACS) pertains to the instable and life-threatening forms of a clinically manifest coronary artery disease with biochemical and/or electrocardiographic evidence od myocyte cell death. In detail, it includes the unstable angina pectoris, the non-ST segment elevation myocardial infarction (NSTEMI) the ST segment elevation myocardial infarction (STEMI) and as well the sudden cardiac death. As early reperfusion of ischaemic myocardium is the most effective way for limiting infarct size by restoring the balance between myocardial oxygen supply and demand, it is the most important therapeutic goal to achieve early and complete antegrade flow in the occluded or restricted vessel, related with a reduction of short and longtime complications as heart failure and severe arrhythmias. It is generally accepted, that the primary percutaneous coronary intervention (PCI) is the method of choice in acute myocardial infarction (STEMI) to restore TIMI-3 blood flow in occluded coronary arteries, if this can be performed within two hours of symptom onset and by a highly specialized team. Since this requirements are only met in 20% of hospitals caring for patients with STEMI in Germany, the therapy with thrombolytic and anticoagulant agents plays still an important role. Apart from a rapid and effective prehospital primary care, it depends furthermore on a differentiated anticoagulatory and antithrombotic therapy during coronary intervention to get optimal results.

Schlüsselwörter

Akutes Koronasyndrom - primäre perkutane Koronarintervention - Fibrinolyse - Thrombozytenaggregationshemmung

Keywords

Acute coronary syndrome - percutaneous coronary intervention - fibrinolytic therapy - antithrombin therapy - antiplatelet therapy
 

  • Literatur

  • 1 Andersen HR, Nielsen TT, Rasmussen K. et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349: 733-42.
    CrossrefPubMedGoogle Scholar
  • 2 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BJM 2002; 324: 71-86.
    CrossrefPubMedGoogle Scholar
  • 3 Antman EM, Giugliano CM, Gibson CM. et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99: 2720-32.
    CrossrefPubMedGoogle Scholar
  • 4 Arntz HR, Strasser RH, Andresen D. et al. Prähospitale Versorgung von Patienten mit akutem ST-Streckenhebungsinfarkt. Z Kardiol 2004; 93: 915-6.
    CrossrefPubMedGoogle Scholar
  • 5 Arntz HR, Tebbe U, Schuster HP. et al. Leitlinien zu Diagnostik und Therapie des akuten Herzinfarktes in der Prähospitalphase. Z Kardiol 2000; 89: 364-72.
    CrossrefPubMedGoogle Scholar
  • 6 Bertrand ME, Rupprecht HJ, Urban P. et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent Interventional Cooperative Study (CLASSICS). Circulation 2001; 102: 624.
    PubMedGoogle Scholar
  • 7 Bertrand ME, Simoons ML, Fox KA. et al. for the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndroms in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-40.
    CrossrefPubMedGoogle Scholar
  • 8 Bode C, Hanson SR, Schmedje JF. et al. Antithrombotic potency of hirudin is increased in nonhuman primates bx fibrin targeeting. Circulation 1997; 95: 800-4.
    CrossrefPubMedGoogle Scholar
  • 9 Bode C, Matsueda GR, Hui KY. et al. Antibodydirected urokinase: A specific fibrinolytic agent. Science 1985; 229: 765-7.
    CrossrefPubMedGoogle Scholar
  • 10 Bode C, Runge MS, Branscomb EE. et al. Antibody-directed fibrinolysis: an antibody specific for both. fibrin and tissue plasminogen activator. J Biol Chem 1989; 264: 944-8.
    PubMedGoogle Scholar
  • 11 Bode C, Schönermark S, Schuler G. et al. Efficacy of intravenous prourokinase and a combnation of prourokinase and urohinase in acute myocardial infarction. Am-J-Cardiol 1988; 61: 971-4.
    CrossrefPubMedGoogle Scholar
  • 12 Braunwald E, Antman EM, Beasley JW. et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive Summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2000; 102: 1193-209.
    CrossrefPubMedGoogle Scholar
  • 13 Cannon CP, Weintraub WS, Demopoulos LA. et al. TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)-Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-87.
    CrossrefPubMedGoogle Scholar
  • 14 Cannon CP, Gibson CM, Mc Cabe CH. et al. TNK-tissue plasminogen activator compared with frontloaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998; 98: 2805-14.
    CrossrefPubMedGoogle Scholar
  • 15 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348 (9038): 1329-39.
    CrossrefPubMedGoogle Scholar
  • 16 Cohen M, Demers C, Gurfinkel EP. et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-52.
    CrossrefPubMedGoogle Scholar
  • 17 CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
    CrossrefPubMedGoogle Scholar
  • 18 Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358 (9282): 605-13.
    CrossrefPubMedGoogle Scholar
  • 19 ESPRIT Investigators. Novel dosing regimen of Eptifibatide In Planed Coronary Stent Implantation (ESPRIT): a randomised, placebo controlled trial. Lancet 2000; 356: 2037-44.
    CrossrefPubMedGoogle Scholar
  • 20 FRISC II investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Fragmin and Fast Revascularisation during In-Stability in Coronary artery disease Investigators. Lancet 1999; 354: 708-15.
    CrossrefPubMedGoogle Scholar
  • 21 FRISC II. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 708-15.
    CrossrefPubMedGoogle Scholar
  • 22 GISSI Investigators. Ten year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction. Results of GISSI-1 study. Circulation 1998; 98: 2659-65.
    CrossrefPubMedGoogle Scholar
  • 23 GUSTO Angiographic Investigarors. The effects of tissue plasminogen activator. streptokinase or both on coronary artery patency, ventricular function and survival after myocardial infarction. N Engl J Med 1993; 329: 1615-22.
    CrossrefPubMedGoogle Scholar
  • 24 GUSTO-IIa investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary symptoms. Circulation 1994; 90: 1631-7.
    CrossrefPubMedGoogle Scholar
  • 25 GUSTO Investigators. An internationel randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
    CrossrefPubMedGoogle Scholar
  • 26 GUSTO-III. A comparison of Reteplase with Alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-23.
    CrossrefPubMedGoogle Scholar
  • 27 Hamm C, Arntz HR, Bode C. et al. Leitlinien Akutes Koronarsyndrom Teil 1: Akutes Koronarsyndrom ohne ST-Hebung. Z Kardiol 2004; 93: 72-90.
    CrossrefPubMedGoogle Scholar
  • 28 Hamm C, Arntz HR, Bode C. et al. Leitlinien Akutes Koronarsyndrom Teil 2: Akutes Koronarsyndrom mit ST-Hebung. Z Kardiol 2004; 93: 324-41.
    CrossrefPubMedGoogle Scholar
  • 29 Hamm CW, Goldmann BU, Heeschen C. et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin I. N Engl J Med 1997; 337: 1648-53.
    CrossrefPubMedGoogle Scholar
  • 30 Hamm CW, Ravkilde J, Gerhardt W. et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992; 327: 146-50.
    CrossrefPubMedGoogle Scholar
  • 31 Heijer P, Vermeer F, Ambrosioni E. et al. Evaluation of a weight adjusted single bolus plasminogen activator in patients with myocardial infarction. A double-blind, randomized angiographic trial of lanoteplase vs alteplase. Circulation 1998; 98: 2117-25.
    CrossrefPubMedGoogle Scholar
  • 32 ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17.189 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
    PubMedGoogle Scholar
  • 33 Jähnchen E, Neumann FJ. Aggregationshemmertherapie bei Koronarerkrankungen. In: Roskamm, Neumann, Kalusche et al. Herzkrankheiten. Heidelberg: Springer; 2004: 897-910.
    Google Scholar
  • 34 Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
    CrossrefPubMedGoogle Scholar
  • 35 Libby P. Current concepts of the pathogenesis of the acute coronary syndroms. Circulation 2001; 104: 365-72.
    CrossrefPubMedGoogle Scholar
  • 36 Lincoff AM, Califf RM, van de Werf F. et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA 2002; 288: 2130-5.
    CrossrefPubMedGoogle Scholar
  • 37 Mehta SR, Yusuf S, Peters RJG. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE Study. Lancet 2001; 358: 527-33.
    CrossrefPubMedGoogle Scholar
  • 38 Menon V. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 549S-75S.
    CrossrefPubMedGoogle Scholar
  • 39 Neuhaus K, Molhoek G, Zeymer U. et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction. Results of the HIT-4 Trial. J Am Coll Cardiol 1999; 34: 966-73.
    CrossrefPubMedGoogle Scholar
  • 40 Neuhaus KL, von Essen R, Tebbe U. et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase : results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol 1992; 19: 885-91.
    CrossrefPubMedGoogle Scholar
  • 41 Oler A, Whooley MA, Oler J. et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996; 276: 811-5.
    CrossrefPubMedGoogle Scholar
  • 42 PRIMI Trial Study Group. Randomized double-blind trial of recombinant prourokinase against streptokinase in acute mycardial infarction. Lancet 1989; 1: 863-8.
    PubMedGoogle Scholar
  • 43 PRISM Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505.
    CrossrefPubMedGoogle Scholar
  • 44 PRISM-Plus Investigators. Inhibition of the platelet glycoprotein IIb/IIIa with tirofiban in unstable angina and non-Q-Wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
    CrossrefPubMedGoogle Scholar
  • 45 Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100: 1667-72.
    CrossrefPubMedGoogle Scholar
  • 46 Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115-25.
    CrossrefPubMedGoogle Scholar
  • 47 Runge MS, Harker LA, Bode C. et al. Enhanced thrombolytic and antithrombotic potency of a fibrin targeted plasminogen activator in baboons. Circulation 1996; 94: 1412-22.
    CrossrefPubMedGoogle Scholar
  • 48 Single-bolus tenecteplase compared with frontloaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999; 354 (9180): 716-22.
    CrossrefPubMedGoogle Scholar
  • 49 Smalling RW, Bode C, Kalbfleisch J. et al. the RAPID Investigators. More rapid complete and stable coronary thrombosis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995; 91: 2725-32.
    CrossrefPubMedGoogle Scholar
  • 50 Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000; 101: 2788-94.
    CrossrefPubMedGoogle Scholar
  • 51 The InTIME-II Investigators. InTIME II, a double blind comparison of single bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000; 21: 2005-13.
    CrossrefPubMedGoogle Scholar
  • 52 The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined – a consensus document of the joint european society of cardiology/american college of cardiology for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-13.
    CrossrefPubMedGoogle Scholar
  • 53 Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357 (9272): 1905-14.
    CrossrefPubMedGoogle Scholar
  • 54 Tunstall-Pedoe H, Kuulasmaa K, Mahonen M. et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 1547-57.
    CrossrefPubMedGoogle Scholar
  • 55 Van de Werf F, Ardissino D, Betriu A. et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003; 24: 28-66.
    PubMedGoogle Scholar
  • 56 Van de Werf F, Cannon CP, Luyten A. et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J 1999; 137: 786-91.
    CrossrefPubMedGoogle Scholar
  • 57 Wallentin L, Goldstein P, Armstrong PW. et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003; 108: 135-42.
    CrossrefPubMedGoogle Scholar
  • 58 Zeymer U, Neuhaus KL. Fibrinolytika. In: Roskamm, Neumann, Kalusche et al. Herzkrankheiten. Heidelberg: Springer; 2004: 911-26.
    Google Scholar